Trials / Unknown
UnknownNCT03855423
Maximum Tolerated Dose, Safety and Pharmacologic Study of TRF in Women With Breast Cancer
Malaysian Tocotrienol Rich Fraction: Immunomodulatory Effect in Women With Breast Cancer
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Nur Aishah Mohd Taib · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase Ib: Maximum Tolerated Dose, Safety and Pharmacologic Study of TRF in Women with Breast Cancer is aimed to determine the highest, safest and tolerable dose of Tocotrienol-rich Fraction (maximal tolerated dose: MTD) that can be used in women with breast cancer.
Detailed description
3+3 step up design method will be used in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Tocotrienol-rich Fraction (TRF) | TRF consists of alpha, gamma and delta tocotrienols in addition to small amount of alpha-tocopherol |
Timeline
- Start date
- 2019-02-18
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
- First posted
- 2019-02-26
- Last updated
- 2019-04-19
Locations
1 site across 1 country: Malaysia
Source: ClinicalTrials.gov record NCT03855423. Inclusion in this directory is not an endorsement.